Paul Josephs - 20 May 2024 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Role
Chief Executive Officer, Director
Signature
/s/ Rebecca J Hilt Attorney-In-Fact for Paul Josephs
Issuer symbol
LFCR
Transactions as of
20 May 2024
Net transactions value
$0
Form type
4
Filing time
22 May 2024, 17:48:54 UTC
Next filing
10 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LFCR Common Stock Award +525,000 525,000 20 May 2024 Direct F1
transaction LFCR Common Stock Tax liability -8,975 -1.7% 516,025 20 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LFCR Performance-Based Restricted Stock Units Award $0 +1,500,000 $0.000000* 0 20 May 2024 Common Stock 1,500,000 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones.
F4 The performance-based restricted stock units vest, if it all, based on the Issuer's achievement of certain stock prices.